Harpoon Therapeutics (NASDAQ:HARP) Reaches New 1-Year High at $25.00

Harpoon Therapeutics Inc (NASDAQ:HARP) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $25.00 and last traded at $21.11, with a volume of 653300 shares. The stock had previously closed at $21.11.

Several brokerages have recently commented on HARP. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Harpoon Therapeutics in a report on Thursday, May 14th. SunTrust Banks assumed coverage on Harpoon Therapeutics in a research note on Thursday, February 27th. They issued a “buy” rating and a $31.00 price target for the company. BidaskClub upgraded Harpoon Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research downgraded shares of Harpoon Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, TheStreet upgraded shares of Harpoon Therapeutics from a “d” rating to a “c-” rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $26.29.

The stock has a 50-day moving average of $12.84 and a 200 day moving average of $14.44. The stock has a market cap of $527.75 million, a PE ratio of -9.47 and a beta of 0.84. The company has a quick ratio of 5.40, a current ratio of 5.40 and a debt-to-equity ratio of 0.16.

Harpoon Therapeutics (NASDAQ:HARP) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.11). The business had revenue of $3.30 million for the quarter, compared to analyst estimates of $7.58 million. Harpoon Therapeutics had a negative net margin of 681.41% and a negative return on equity of 53.62%. On average, equities analysts anticipate that Harpoon Therapeutics Inc will post -1.97 EPS for the current year.

In other Harpoon Therapeutics news, insider Natalie Sacks sold 4,556 shares of Harpoon Therapeutics stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $12.06, for a total transaction of $54,945.36. Following the completion of the transaction, the insider now owns 50,310 shares in the company, valued at approximately $606,738.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 22,701 shares of company stock worth $299,637. 34.90% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in HARP. Russell Investments Group Ltd. purchased a new position in shares of Harpoon Therapeutics during the 4th quarter valued at approximately $315,000. Victory Capital Management Inc. grew its position in Harpoon Therapeutics by 51.7% during the fourth quarter. Victory Capital Management Inc. now owns 2,662 shares of the company’s stock valued at $35,000 after buying an additional 907 shares during the period. State Street Corp increased its holdings in Harpoon Therapeutics by 15.5% in the fourth quarter. State Street Corp now owns 123,887 shares of the company’s stock valued at $1,832,000 after buying an additional 16,660 shares in the last quarter. Barclays PLC raised its position in shares of Harpoon Therapeutics by 87.2% in the fourth quarter. Barclays PLC now owns 12,220 shares of the company’s stock worth $180,000 after acquiring an additional 5,691 shares during the period. Finally, Citigroup Inc. boosted its stake in shares of Harpoon Therapeutics by 92.8% during the 4th quarter. Citigroup Inc. now owns 3,471 shares of the company’s stock worth $51,000 after acquiring an additional 1,671 shares in the last quarter. Institutional investors and hedge funds own 77.36% of the company’s stock.

About Harpoon Therapeutics (NASDAQ:HARP)

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Read More: Penny Stocks, What You Need To Know

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.